Working… Menu
Trial record 1 of 1 for:    NCT01788683
Previous Study | Return to List | Next Study

Regenexx™ SD Versus Exercise Therapy for Rotator Cuff Tears

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01788683
Recruitment Status : Active, not recruiting
First Posted : February 11, 2013
Last Update Posted : July 27, 2020
Information provided by (Responsible Party):
Regenexx, LLC

Brief Summary:

The primary objective of this study is to compare the improvement in subject-reported clinical outcomes, for Regenexx SD treatment vs. Exercise Therapy of non-retracted supraspinatus tendon tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months.

Secondary objectives include evaluation of US evidence of tendon repair; incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score and use of pain medications.

Condition or disease Intervention/treatment Phase
Rotator Cuff Tear Procedure: Regenexx SD Other: Exercise Therapy Not Applicable

Detailed Description:

Prospective, randomized, controlled to include 34 subjects treated with Regenexx SD and 17 subjects treated with Exercise Therapy alone (2:1 randomization).

Subjects will have a non-retracted supraspinatus tendon tear comprising at least one half the tendon thickness in the anterior-posterior and/or superior-inferior planes as evidenced with positive diagnostic imaging such as arthrogram, ultrasound and/or MR.

Subjects will be enrolled within 60 days prior to Regenexx-SD injection or initiation of exercise therapy and take part in follow-up visits for two years following treatment. A preoperative visit will occur at the time of enrollment; follow-up visits will occur at the clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post injection.

The primary endpoint analysis will be conducted once all subjects reach the 3 month endpoint. At that point, subjects enrolled in the Exercise Therapy group will be given the option of crossing over to the Regenexx SD treatment groups. Subjects will continue to be followed through the 2 year endpoint with data analysis performed at the 1 year and 2 year time points.

Subjects will complete the study following the 2 year follow-up visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Non-retracted Supraspinatus Tendon Tears
Study Start Date : February 2013
Actual Primary Completion Date : May 2020
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Regenexx SD
Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged tendon.
Procedure: Regenexx SD
stem cell treatment

Active Comparator: Exercise Therapy
Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.
Other: Exercise Therapy
exercise therapy control

Primary Outcome Measures :
  1. DASH Score Change from Baseline [ Time Frame: Change from Baseline to 3 months ]
    The primary endpoint for this study is the difference between treatment groups in the within patient mean change from baseline to 3 months in Disabilities of the Arm Shoulder and Hand (DASH) scores.

Secondary Outcome Measures :
  1. Mean Pain Scales [ Time Frame: 3, 6, 12 and 24 months ]
    Difference between treatment groups in mean 0-10 pain scales at each follow-up timepoint

  2. MRI evidence of tendon repair [ Time Frame: 12 months ]
    Comparison between groups of MRI evidence of tendon repair at 12 months

  3. Mean DASH scores [ Time Frame: 6, 12 and 24 months ]
    Difference between treatment groups in mean Disabilities of Arm Shoulder and Hand (DASH) scores at 6, 12 and 24 months.

  4. Incidence of Complications and Adverse Events [ Time Frame: 24 months ]
    Incidence and time to resolution of post-operative complications and adverse events between treatment groups.

  5. Incidence of re-injection and surgical revision [ Time Frame: 24 months ]
    Incidence of and time to re-injection and surgical revision between treatment groups.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Physical examination consistent with Rotator Cuff tear
  • Unremitting pain in the affected shoulder for at least 3 months
  • Significant functional disability related to pain, lack of strength, or other shoulder symptoms
  • Positive diagnostic imaging, which may include arthrogram, ultrasound and/or MR, on the affected shoulder indicating a non-retracted supraspinatus tendon tear comprising at least one half the tendon thickness in the anterior-posterior and/or superior-inferior planes
  • Reasonable movement of the non-treated arm, defined as a shoulder elevation of equal or more than 90°, and able to perform (post-injection) exercises
  • Is independent, ambulatory, and can comply with all post-operative evaluations and visits

Exclusion Criteria:

  • A massive rotator cuff tear as demonstrated by Grade 3 or less muscle strength on testing internal and external rotation of the affected shoulder
  • Previous surgery to the affected shoulder
  • Concomitant tears of biceps tendons
  • Grade 2 or greater SLAP tear
  • Type 3 acromion
  • Significant bone spur in subacromial space
  • Inflammatory or auto-immune based joint diseases or other upper extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)
  • Quinolone or Statin induced myopathy/ tendinopathy
  • Kellgren-Lawrence grade 2 or greater glenohumeral osteoarthritis
  • Adhesive capsulitis (mild or severe)
  • Symptomatic cervical spine pathology (e.g. radicular cervical pain)
  • Severe neurogenic inflammation of the cutaneous nerves about the shoulder
  • Shoulder instability requiring surgical stabilization
  • Contraindications for MRI
  • Tested positive or has been treated for a malignancy in the past or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site
  • Condition represents a worker's compensation case
  • Currently involved in a health-related litigation procedure
  • Is pregnant
  • Bleeding disorders
  • Currently taking anticoagulant or immunosuppressive medication
  • Use of chronic opioid

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01788683

Layout table for location information
United States, Colorado
Centeno-Schultz Clinic
Broomfield, Colorado, United States, 80021
Sponsors and Collaborators
Regenexx, LLC
Layout table for investigator information
Principal Investigator: Christopher Centeno, MD Centeno-Schultz Clinic
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Regenexx, LLC Identifier: NCT01788683    
Other Study ID Numbers: RSI2012-RCT01
First Posted: February 11, 2013    Key Record Dates
Last Update Posted: July 27, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Regenexx, LLC:
Rotator Cuff
Rotator Cuff Tear
Supraspinatus Tear
Additional relevant MeSH terms:
Layout table for MeSH terms
Rotator Cuff Injuries
Wounds and Injuries
Shoulder Injuries
Tendon Injuries